Sailaja Puttagunta - 10 Dec 2021 Form 4 Insider Report for Iterum Therapeutics plc (ITRM)

Role
Chief Medical Officer
Signature
/s/ Sailaja Puttagunta
Issuer symbol
ITRM
Transactions as of
10 Dec 2021
Net transactions value
$0
Form type
4
Filing time
14 Dec 2021, 16:00:19 UTC
Previous filing
13 Dec 2021
Next filing
05 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITRM Share Option (Right to Buy) Award $0 +1,800,000 $0.000000 1,800,000 10 Dec 2021 Ordinary Shares 1,800,000 $0.4800 Direct F1
transaction ITRM Restricted Share Units Award $0 +500,000 $0.000000 500,000 10 Dec 2021 Ordinary Shares 500,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of December 1, 2021 and the remaining 75% will vest in equal monthly installments thereafter until December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.
F2 Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.
F3 Subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date and the other terms and conditions of the Issuer's 2021 Inducement Equity Incentive Plan, the RSUs shall vest over four years with 25% of the RSUs vesting on each one-year anniversary of December 1, 2021, such that the total number of RSUs shall be fully vested by December 1, 2025.